Nucleic Acid Amplification Testing Market Report 2026

Nucleic Acid Amplification Testing Market Overview

• Nucleic Acid Amplification Testing market size has reached to $11.03 billion in 2025 • Expected to grow to $22.1 billion in 2030 at a compound annual growth rate (CAGR) of 14.8% • Growth Driver: Infectious Diseases Propel Growth Of The Nucleic Acid Amplification Testing Market • Market Trend: Innovative IVD Assays Revolutionizing CMV Screening In The Nucleic Acid Amplification Testing Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Nucleic Acid Amplification Testing Market?

Nucleic acid amplification testing (NAAT) refers to molecular techniques that detect and amplify specific deoxyribose nucleic acid (DNA) or ribose nucleic acid (RNA) in a sample. It is widely used for identifying pathogens at early infection stages due to its high sensitivity. Researchers use NAAT to study gene expression, genetic variations, and disease mechanisms, aiding in understanding genetic disease bases and developing targeted therapies. The main types of nucleic acid amplification testing are target amplification systems, probe amplification systems, and signal amplification systems. Target amplification systems are techniques for amplifying specific nucleic acid sequences in a sample, vital for enhancing sensitivity and accuracy in nucleic acid amplification testing (NAAT). The product types include consumables and instruments or systems with various technologies, such as polymerase chain reaction (PCR) tests, isothermal nucleic acid amplification technology (INAAT) tests, and ligase chain reaction (LCR) tests. It is used in several applications, including infectious disease testing, oncology testing, genetic and mitochondrial disease testing, and others, and by various end-uses such as hospitals, diagnostic laboratories, biotechnology companies, and others.

What Is The Nucleic Acid Amplification Testing Market Growth Forecast?

The nucleic acid amplification testing market size is expected to see rapid growth in the next few years. It will grow to $22.1 billion in 2030 at a compound annual growth rate (CAGR) of 14.8%. The growth in the forecast period can be attributed to personalized medicine growth, demand for rapid diagnostics, expansion in emerging markets, technological miniaturization, regulatory approvals for novel assays. Major trends in the forecast period include rapid point-of-care molecular testing, expansion of multiplex and syndromic panels, rising adoption of isothermal amplification techniques, growth in home-based and decentralized testing, increasing focus on early disease detection.

Global Nucleic Acid Amplification Testing Market Segmentation

1) By Type: Target Amplification Systems, Probe Amplification Systems, Signal Amplification Systems 2) By Amplification Method: Consumables, Instruments Or Systems 3) By Technology: Polymerase Chain Reaction (PCR) Tests, Isothermal Nucleic Acid Amplification Technology (INAAT) Tests, Ligase Chain Reaction (LCR) Tests 4) By Application: Infectious Disease Testing, Oncology Testing, Genetic And Mitochondrial Disease Testing, Other Applications 5) By End-Use: Hospitals, Diagnostic Laboratories, Biotechnology Companies, Other End-Users Subsegments: 1) By Target Amplification Systems: Polymerase Chain Reaction (PCR), Real-Time PCR (qPCR), Reverse Transcription PCR (RT-PCR), Nested PCR, Multiplex PCR, LAMP (Loop-Mediated Isothermal Amplification), 2) By Probe Amplification Systems: Nucleic Acid Sequence-Based Amplification (NASBA), Hybridization-Based Amplification, Branch Chain Amplification (BCA), Strand Displacement Amplification (SDA), 3) By Signal Amplification Systems: Enzyme-Linked Signal Amplification, Fluorescent Signal Amplification, Chemiluminescent Signal Amplification, Electrochemical Signal Amplification, Magnetic Particle-Based Signal Amplification

What Is The Driver Of The Nucleic Acid Amplification Testing Market?

The increasing incidence of infectious diseases is expected to propel the growth of the nucleic acid amplification testing market going forward. Infectious diseases are conditions caused by organisms that can spread directly or indirectly from one person to another via various means, such as physical contact, airborne transmission, contaminated food or water, or vector-borne spread via insects. The increase in infectious diseases is due to antibiotic resistance, climate change, changes in human behavior, and agricultural practices. Nucleic acid amplification testing (NAAT) rapidly and accurately identifies infectious pathogens, facilitating timely diagnosis and treatment, thereby helping to control the spread of diseases. For instance, in October 2023, according to the Public Health Agency of Canada, a Canada-based government agency, in the 2022–2023 season, participating provinces and territories reported 4,216 hospitalizations related to influenza. Therefore, the increasing incidence of infectious diseases drives the growth of the nucleic acid amplification testing industry.

Key Players In The Global Nucleic Acid Amplification Testing Market

Major companies operating in the nucleic acid amplification testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Merck KGaA, Siemens Healthineers, Becton Dickinson and Company, Laboratory Corporation of America Holdings, Quest Diagnostics, Agilent Technologies Inc., Grifols S.A., Hologic Inc., bioMerieux SA, QuidelOrtho Corporation, Bio-Rad Laboratories Inc., Cepheid Inc., GenScript Biotech Corporation, ARUP Laboratories, BGI Group, Promega Corporation, Meridian Bioscience Inc., Takara Bio Inc., Eiken Chemical Co. Ltd., New England Biolabs Inc., TwistDx Limited, Bioneer Corporation

Global Nucleic Acid Amplification Testing Market Trends and Insights

Major companies operating in the nucleic acid amplification testing market are focusing on developing innovative solutions, such as in vitro diagnostics (IVD) assays, to screen donated blood for CMV by nucleic acid amplification technology (NAT) under the IVDR. An IVD (in vitro diagnostic) assay is a test performed on biological samples to detect diseases, conditions, or infections outside the body in a laboratory setting. For instance, in June 2024, GFE, a Germany-based company, launched the PoET CMV. PoET CMV, an IVD assay, is designed for the rapid and precise detection of cytomegalovirus (CMV) infections. Its unique features include high sensitivity and specificity, allowing for early diagnosis and effective monitoring of CMV in transplant patients and immunocompromised individuals. The assay utilizes advanced molecular techniques to deliver reliable results quickly, supporting timely clinical decision-making.

What Are Latest Mergers And Acquisitions In The Nucleic Acid Amplification Testing Market?

In July 2024, Roche Holding AG, a Switzerland-based pharmaceutical company, acquired LumiraDx for an undisclosed amount. With this acquisition, Roche will expand its diagnostics section and offer a broader variety of immunoassay and clinical chemistry tests, thorough, high-value testing without the need for specialized cold storage, making it suited for a variety of healthcare settings while also improving testing efficiency and patient outcomes, particularly in primary care and underserved areas. LumiraDx is a UK-based provider of nucleic acid amplification testing.

Regional Outlook

North America was the largest region in the nucleic acid amplification testing (NAAT) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Nucleic Acid Amplification Testing Market?

The nucleic acid amplification testing (NAAT) market consists of revenue earned by entities by provide services such as genetic disorder screening, environmental testing, infectious disease diagnosis, and pharmacogenomics. The market value includes the value of related goods sold by the service provider or included within the service offering. The nucleic acid amplification testing (NAAT) market also includes sales of reagents, pre-packaged kits, test tubes, pipettes, and plates. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.